SCHEMBL1464175

SCHEMBL1464175

CCCCCCCCCCCCCCC(O)(SC(O)(CCCCCCCCCCCCCC)C(=O)O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 8/20 0.44
GGPS1 O95749 5/20 0.44
HSD17B10 Q99714 2/20 0.44
GMNN O75496 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
BLM P54132 1/20 0.44
CES2 O00748 1/20 0.42
PPARG P37231 3/20 0.41
PPARD Q03181 3/20 0.41
PPARA Q07869 3/20 0.41
TSHR P16473 2/20 0.41
GPR84 Q9NQS5 2/20 0.41
HDAC11 Q96DB2 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464122 1.00 FDPS (0.44) FDPSGGPS1HSD17B10GMNNTP53
SCHEMBL17183982 0.91 HSD17B10 (0.38) HSD17B10GMNNTP53POLBMAPT
SCHEMBL7779023 0.88 FDPS (0.44) FDPSGGPS1HSD17B10GMNNTP53
SCHEMBL11550381 0.82 GMNN (0.48) FDPSGGPS1HSD17B10GMNNTP53
SCHEMBL7774055 0.78 HSD17B10 (0.38) HSD17B10GMNNTP53POLBMAPT
SCHEMBL30409240 0.77 CES2 (0.44) GGPS1HSD17B10CES2PPARGPPARD
SCHEMBL11351778 0.76 FDPS (0.48) FDPSGGPS1HSD17B10CES2PPARG
SCHEMBL380072 0.76 FDPS (0.48) FDPSGGPS1HSD17B10CES2PPARG
SCHEMBL1990820 0.76 FDPS (0.48) FDPSGGPS1HSD17B10CES2PPARG
SCHEMBL11220213 0.76 FDPS (0.48) FDPSGGPS1HSD17B10CES2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362014-B2 ABT-263 crystalline forms ABBVIE INC. (US) 2013-01-29 US disclosed
US-20110071151-A1 ABT-263 CRYSTALLINE FORMS ABBOTT LABORATORIES (US) 2011-03-24 US disclosed
US-20100323020-A1 STABLE NANOPARTICULATE DRUG SUSPENSION ABBOTT LABORATORIES (US) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100323020-A1 STABLE NANOPARTICULATE DRUG SUSPENSION BCL2L10, TMBIM6, BCOR FDPS 4484/4885GGPS1 4385/4885HSD17B10 2721/4885
US-20110071151-A1 ABT-263 CRYSTALLINE FORMS BCL3, BCL2, BCL2L13 FDPS 4433/4885GGPS1 4504/4885HSD17B10 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.